News >

Following Pivotal Trials, Questions Remain With Bevacizumab in Recurrent Ovarian Cancer

Angelica Welch
Published: Friday, Dec 14, 2018

Valerie Sugiyama, MD

Valerie Sugiyama, MD

Patients with recurrent ovarian cancer have various treatment options, the choice of which may depend on the way the cancer presents. Although many patients benefit from cytoreductive surgery and chemotherapy and experience prolonged remissions, some histologies retain a poor prognosis.

In a presentation during the 2018 OncLive® State of the Science Summit™ on Ovarian Cancer and Soft Tissue Sarcoma, Valerie Sugiyama, MD, clinical assistant professor of obstetrics and gynecology and gynecologic oncology at Stanford Healthcare, discussed the treatment of patients with recurrent ovarian cancer.

Some standard chemotherapy agents used in patients with recurrent disease are gemcitabine, topotecan, docetaxel, etoposide, liposomal doxorubicin, taxane, and platinum. However, patients who are resistant to platinum tend to experience recurrence within 6 months of their frontline chemotherapy. Resistant patients tend to have shortened progression-free survival (PFS) and overall survival (OS).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ASCO Direct™ Highlights – 2019 Official Annual Meeting ReviewAug 30, 20201.5
Community Practice Connections™: Advances in Ovarian Cancer: Evolving Applications for PARP Inhibitors, Immunotherapy & Beyond!Aug 30, 20201.5
Publication Bottom Border
Border Publication